1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Scrip Intelligence presents its latest Roundtable on Managing Biotechs

 
• By Alexandra Shimmings

Scrip Intelligence has released its latest Roundtable discussion, Capital Efficiency: Managing Biotechs in Straitened Times.

Scrip Intelligence has released its latest Roundtable discussion, Capital Efficiency: Managing Biotechs in Straitened Times.

In London at the beginning of December, Scrip Intelligence hosted a Roundtable discussion, chaired by editor-in-chief Mike Ward, to discuss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

More from Therapy Areas